सत्याधीशसत्याधीश
SatyaDheesh
India's Ground Truth Record
Pull to refresh
VOL. I · EST. 11.2025 
SatyaDheesh
सत्याधीश
India's Ground Truth Record
LIVE

The International Agency for Research on Cancer (IARC), part of the World

GS3Economy · S&T · Environment · Security· Biotechnology & health research· Prelims·

Why in news

The IARC (part of WHO) classified three common medicines as carcinogenic to humans, highlighting the need for balanced risk-benefit analysis in pharmacology.

Background

On August 4, 2026, the IARC classified hydrochlorothiazide (hypertension), voriconazole (fungal infections), and tacrolimus (organ transplant rejection) as carcinogenic. These drugs are included in the WHO's essential medicines list.

Facts for Prelims

  • BodyIARC: International Agency for Research on Cancer, a specialized agency of the WHO.
  • FactHydrochlorothiazide is used to treat hypertension.
  • FactVoriconazole is used to treat fungal infections.
  • FactTacrolimus is used to prevent organ transplant rejection.

For Mains

Q. Discuss the challenges in balancing the accessibility of essential medicines with the long-term safety risks associated with carcinogenic side effects.

Dimensions to cover in your answer

  • public health safety
  • regulatory oversight
  • patient-doctor communication
  • WHO essential medicines list

Keywords: carcinogenic · pharmacovigilance · essential medicines · risk-benefit analysis

Read the full news →Report a mistake in this noteHow notes are madeSource: The Hindu ↗Also: GS2 · Health policy & public health

More Science & Technology notes

All Science & Technology current affairs →

Something wrong, or something missing?

Spotted a mistake in a note, or want a topic, format or PDF that would help your preparation? Write to us. We read every mail and fix errors fast.

Report a mistake →Ask for something →[email protected]

This note is generated automatically from SatyaDheesh's news feed and mapped to the UPSC CSE syllabus. Check facts against the original report or PIB before using them in an answer.